Highland Global Allocation Fund Adopts Sweeping Anti-Takeover and Shareholder Rights Restrictions
summarizeSummary
Highland Global Allocation Fund approved significant amendments to its Declaration of Trust and Bylaws, introducing stringent anti-takeover provisions and substantially restricting shareholder rights regarding litigation, proposals, and trustee nominations.
check_boxKey Events
-
Adoption of Restated Governance Documents
The Board approved the Second Amended and Restated Declaration of Trust and Third Amended and Restated Bylaws, effective January 27, 2026.
-
Implementation of Anti-Takeover Measures
New provisions include control share acquisition rules, requiring shareholder approval for voting rights of large ownership blocks, and granting the Trust redemption rights for unapproved control shares. Certain transactions with 'Principal Shareholders' now require a 75% shareholder vote.
-
Restrictions on Shareholder Rights
New rules impose strict demand and authorization requirements for derivative and direct shareholder claims, establish Massachusetts as the exclusive forum for disputes, and significantly tighten advance notice and qualification requirements for shareholder proposals and trustee nominations.
-
Board Reclassification
Dorri McWhorter was reappointed as a Class I Trustee following the passing of Bryan A. Ward, maintaining her role as audit committee chair.
auto_awesomeAnalysis
The company's adoption of the Second Amended and Restated Declaration of Trust and Third Amended and Restated Bylaws represents a critical shift in its corporate governance structure. Key changes include the implementation of control share acquisition provisions, which require shareholder approval for voting rights of large ownership blocks and allow the Trust to redeem unapproved control shares. Additionally, the amendments introduce an exclusive forum selection clause, mandating that all covered legal actions be brought in Massachusetts courts, and impose highly restrictive advance notice and qualification requirements for shareholder proposals and trustee nominations. These measures are designed to significantly limit shareholder activism, deter potential takeovers, and entrench the current board and management, which is a substantial negative for investor influence and corporate accountability.
At the time of this filing, HGLB was trading at $8.72 on NYSE in the Unknown sector. The 52-week trading range was $6.62 to $10.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.